Key result
VXX-401 PCSK9 vaccine achieves superior LDL-C lowering compared to alternative vaccine candidates in preclinical meta-analysis.
Why the study?
Which PCSK9-targeted vaccine design is most effective for lowering LDL-C in dyslipidemic nonhuman primates?
Meta-Analysis
Which PCSK9-targeted vaccine design is most effective for lowering LDL-C in dyslipidemic nonhuman primates?
Answers are grounded in this paper and cite their sources.
In a network meta-analysis of nonhuman primate models, the VXX-401 PCSK9-targeted vaccine was the most effective design for lowering LDL-C, supporting its potential for further atherosclerosis vaccine development.
BACKGROUND: The regulation of plasma low-density lipoprotein cholesterol (LDL-C) levels and low-density lipoprotein receptor (LDLR) function is largely dependent on proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9-targeted vaccinations have been designed to produce PCSK9-specific antibodies, which may improve dyslipidemia and lower the risk of cardiovascular disease. The purpose of this study was to conduct a frequentist network meta-analysis of animal trials to determine the most effective PCSK9 vaccine designs for improving lipid profiles. METHODS: A comprehensive search of PubMed, Scopus, and Web of Science for studies published before October 2024 was carried out. There were studies that used PCSK9-targeted vaccinations in dyslipidemic nonhuman primates. The analysis utilized a random-effects model with effect size metrics of standardized mean difference and 95% confidence intervals. Heterogeneity was investigated using I² statistics. RESULTS: Four studies published between 2021 and 2024 satisfied the inclusion requirements, covering five vaccine designs with different epitope sequences, delivery mechanisms, and carriers. Three vaccine designs have significant effect in lowering LDL-C: (1) vaccine designed with a full peptide immunogen containing T-helper and B-cell epitopes (VXX-401, P < 0.025); (2) vaccine designed with linear PCSK9-derived epitopes with Qß bacteriophage virus-like particles (rhPCSK9 VLPs, P < 0.001); (3) PCSK9 mimic (cleavage-resistant mutant) linked to shark-derived scaffold (HIT01-K21Q-R218E, P < 0.037). The VXX-401 vaccine has higher effectiveness as compared to rhPCSK9 VLPs ( P = 0.005) and HIT01-K21Q-R218E ( P = 0.007). Heterogeneity was low to moderate in all studies ( I ² =0%–26%). CONCLUSION: Because of its improved lipid-lowering performance in animal studies, VXX-401 is being considered a prospective option for further studies in atherosclerosis vaccine. The findings from the present study offer a valuable insight to the advancement of therapeutic strategies in atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Muzaffar et al. (2025) conducted a meta-analysis in Dyslipidemia. PCSK9-targeted vaccinations (e.g., VXX-401) vs. Other vaccine designs (e.g., rhPCSK9 VLPs, HIT01-K21Q-R218E) was evaluated on Lowering of low-density lipoprotein cholesterol (LDL-C) (p=0.005). The VXX-401 PCSK9-targeted vaccine demonstrated higher effectiveness in lowering LDL-C compared to rhPCSK9 VLPs and HIT01-K21Q-R218E in nonhuman primates.
Synapse has enriched 10 related papers. Consider them for comparative context: